189 related articles for article (PubMed ID: 32125937)
21. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.
Rauch GM; Kuerer HM; Scoggins ME; Fox PS; Benveniste AP; Park YM; Lari SA; Hobbs BP; Adrada BE; Krishnamurthy S; Yang WT
Breast Cancer Res Treat; 2013 Jun; 139(3):639-47. PubMed ID: 23774990
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
23. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
24. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
26. Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Kim J; Lim W; Kim EK; Kim MK; Paik NS; Jeong SS; Yoon JH; Park CH; Ahn SH; Kim LS; Han S; Nam SJ; Kang HS; Kim SI; Yoo YB; Jeong J; Kim TH; Kang T; Kim SW; Jung Y; Lee JE; Kim KS; Yu JH; Chae BJ; Jung SY; Kang E; Choi SY; Moon HG; Noh DY; Han W
BMC Cancer; 2014 Mar; 14():170. PubMed ID: 24612502
[TBL] [Abstract][Full Text] [Related]
27. Everolimus Plus Letrozole for Treatment of Patients With HR
Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
[TBL] [Abstract][Full Text] [Related]
28. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
[TBL] [Abstract][Full Text] [Related]
29. Predicting Upgrade of Ductal Carcinoma In Situ to Invasive Breast Cancer at Surgery With Ultrafast Imaging.
Miceli R; Gao Y; Qian K; Heller SL
AJR Am J Roentgenol; 2023 Jul; 221(1):34-43. PubMed ID: 36752370
[No Abstract] [Full Text] [Related]
30. Impact of breast MRI in women eligible for breast conservation surgery and intra-operative radiation therapy.
Paudel N; Bethke KP; Wang LC; Strauss JB; Hayes JP; Donnelly ED
Surg Oncol; 2018 Mar; 27(1):95-99. PubMed ID: 29549911
[TBL] [Abstract][Full Text] [Related]
31. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
32. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
33. Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS.
Balleyguier C; Dunant A; Ceugnart L; Kandel M; Chauvet MP; Chérel P; Mazouni C; Henrot P; Rauch P; Chopier J; Zilberman S; Doutriaux-Dumoulin I; Jaffre I; Jalaguier A; Houvenaeghel G; Guérin N; Callonnec F; Chapellier C; Raoust I; Mathieu MC; Rimareix F; Bonastre J; Garbay JR
J Clin Oncol; 2019 Apr; 37(11):885-892. PubMed ID: 30811290
[TBL] [Abstract][Full Text] [Related]
34. Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.
Rivera R; Banks A; Casillas-Lopez A; Rashtian A; Lewinsky B; Sheth P; Hovannesian-Larsen L; Brousseau D; Iyengar G; Holmes DR
Breast J; 2016; 22(1):63-74. PubMed ID: 26534876
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
Llombart-Cussac A; Guerrero Á; Galán A; Carañana V; Buch E; Rodríguez-Lescure Á; Ruiz A; Fuster Diana C; Guillem Porta V
Clin Transl Oncol; 2012 Feb; 14(2):125-31. PubMed ID: 22301401
[TBL] [Abstract][Full Text] [Related]
36. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab not for ductal carcinoma in situ?
Nahleh Z; Namakydoust A; Bakkar R; Bishop J
Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
[TBL] [Abstract][Full Text] [Related]
38. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
40. Ductal carcinoma in situ, complexities and challenges.
Leonard GD; Swain SM
J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
